AstraZeneca on Monday announced the successful completion of an equity investment with France-based Cellectis, a clinical-stage biotechnology company.

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has now approved Pfizer’s Oxbryta (voxelotor) to be recommended for use on the National Health Service NHS to ...

The prestigious New England Journal of Medicine (NEJM) has published interim results from the Phase III trial of Japanese drug major Takeda Pharma’s (TYO: 4502) Adzynma (apadamtase ...

Sentynl Therapeutics, the USA-based wholly-owned subsidiary of Indian generics major Zydus Lifesciences (NYSE: ZYDUSLIFE), has announced the closing of the sale of Eiger BioPharmaceuticals’ (OTC: ...

Danish diabetes giant Novo Nordisk (NOV: N) today reported financial results for the first quarter of 2024, noting that sales ...

The UK pharma sector is dynamic, supported by a government-led drive to make the UK a ‘Science Superpower’. 1 This steer from the government, alongside a strong patient advocacy landscape and ...

The UK’s medicines regulator has set out its strategic approach to artificial intelligence (AI).

Osaka, Japan-based drugmaker Ono Pharmaceutical (TYO: 4528) has entered into a drug discovery collaboration agreement with ...

Philadelphia, USA-based Reunion Neuroscience, a company developing psychedelics for the treatment of mental health conditions, has announced the closing of a $103 million Series A financing.

Genmab (CPH: GMAB) continues to thrive. The Danish biotech company reported its financial results for the first quarter of 2024 on Thursday, sending shares up by 5% in the following day’s trading.

California-based biopharma BridgeBio Pharma (Nasdaq: BBIO) has announced the completion of a $200 million private financing of its former subsidiary, TheRas. Doing business as BridgeBio Oncology ...

Swiss pharma giant Novartis (NOVN VX) has entered into an agreement to acquire USA-based biotech start-up Mariana Oncology, which is focused on developing novel radioligand therapies (RLTs) to ...